All Posts Tagged With: "ABT"
(AAPL) Jan 25: All Eyes on the Fed – Economic Highlights
The focus today will be on the Fed, as the central bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today’s...
25Jan2012 | vitalstocks | 0 comments | Continued(AAPL) Focus Moves Toward the Federal Reserve
The focus today will be on the Fed, as the Central Bank unveils a new measure as part of its ongoing efforts to improve communication with the markets. The prospect of an even longer timeframe for lower interest rates, as many in the markets are hoping to come out of today’s...
25Jan2012 | vitalstocks | 0 comments | Continued(ABT) Earnings Season in Full Swing – Earnings Preview
Earnings Preview 1/20/12 Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&P 500. By the end of the week we should have a very good handle on just how weak or strong this earnings season will be. The...
24Jan2012 | vitalstocks | 0 comments | Continued(BIIB) Biogen Analyst Neutral on Shares
We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain a leading position in the MS market. Biogen’s largest product, Avonex,...
21Jan2012 | vitalstocks | 0 comments | Continued(QGEN) Qiagen Expands with New Deals
In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement,...
13Jan2012 | vitalstocks | 0 comments | Continued(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld
by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate...
9Jan2012 | InvestmentU | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook
Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line with expectations. While the Zacks Consensus Earnings Estimate, prior...
27Dec2011 | vitalstocks | 0 comments | Continued(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld
by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate...
21Dec2011 | InvestmentU | 0 comments | Continued(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. —...
7Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and...
5Dec2011 | vitalstocks | 0 comments | Continued(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook
The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures,...
18Nov2011 | vitalstocks | 0 comments | Continued(MS) Oct 19: The Earnings Parade Continues – Economic Highlights
The earnings parade continues even as the market tries to come to terms with the Apple surprise and waits for the expected weekend deal out of Europe. We also have economic data this morning about September CPI and Housing Starts, but they will likely have less traction in today’s...
20Oct2011 | vitalstocks | 0 comments | Continued(MS) Ahead of Wall Street – October 19, 2011 – Ahead of Wall Street
Wednesday, October 19, 2011 The earnings parade continues even as the market tries to come to terms with the Apple surprise and waits for the expected weekend deal out of Europe. We also have economic data this morning about September CPI and Housing Starts, but they will likely...
20Oct2011 | vitalstocks | 0 comments | Continued(AAPL) A Busy Week Ahead – Earnings Preview
Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500. Thus, by the end of the week we will have a very...
17Oct2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(BAC) Market Outlook Murky – Valuations Compelling
The Earnings Picture Second quarter earnings season is over; the attention now shifts to the third quarter. With the exception of a handful of financials, most notably Bank of America (BAC), which had a $12 billion negative swing in net income from last year, this has been another...
20Sep2011 | vitalstocks | 0 comments | Continued(MDT) Medical Devices Stock Outlook – Sept. 2011 – Industry Outlook
June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected...
8Sep2011 | vitalstocks | 0 comments | Continued(GILD) Take Advantage of the Fire Sale in Healthcare
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts...
18Aug2011 | InvestmentU | 0 comments | Continued(ABT) Stock Market News for August 2, 2011 – Market News
The benchmarks’ roller-coaster ride finally came to a stop with markets losing modest points, as manufacturing data spoiled the party after Obama and congressional leaders confirmed they had reached an agreement on the debt ceiling. Investor mood swayed from positive to cautious...
2Aug2011 | vitalstocks | 0 comments | Continued(AMGN) Amgen Beats Earnings Expectations – Updates Outlook
Amgen (AMGN) reported second quarter earnings per share of $1.35, 5 cents above the Zacks Consensus Estimate and 0.7% above the year-ago earnings. Total revenues increased 4% to $3,959 million in the second quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,778...
30Jul2011 | vitalstocks | 0 comments | Continued(AAPL) 2011 Second Quarter Earnings Preview – Detailed
Earnings Preview 7/15/11 Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are in the S&P 500. By next Friday we should have a very good handle on how the overall...
18Jul2011 | vitalstocks | 0 comments | Continued(SRDX) SurModics Analysts Cut Shares to Neutral
We are downgrading SurModics (SRDX) to Neutral from Outperform following its setback, when partner Johnson & Johnson (JNJ) announced in June 2011 that it will stop manufacturing Cypher and Cypher Select Plus sirolimus-eluting coronary stents by year-end. SurModics receives...
10Jul2011 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform
Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion...
1Jul2011 | vitalstocks | 0 comments | Continued(ABT) Abbott Labs and Reata Pharmaceuticals Present New Phase II Data
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of Medicine, the data were also presented at the European Renal Association-European...
29Jun2011 | vitalstocks | 0 comments | Continued(CMED) China Medical Technologies Collaborates to Grow
China Medical Technologies, Inc. (CMED), a Chinese in-vitro diagnostic firm, recently revealed that its whole subsidiary – Beijing GP Medical Technologies Co. Ltd. (“GP Medical”) has agreed to collaborate with Gaoxin Da An Healthcare Investment Ltd. (“Da An...
26Jun2011 | vitalstocks | 0 comments | Continued(ABT) Abbott Labs Boosts Immunology Pipeline
Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061. The Candidate: BT-061 The deal is focused on the development and commercialization of BT-061 for the treatment of rheumatoid...
24Jun2011 | vitalstocks | 0 comments | Continued(MDT) Medical Devices Stock Outlook – June 2011 – Industry Outlook
A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011,...
22Jun2011 | vitalstocks | 0 comments | Continued(USA) Company News for June 20, 2011 – Corporate Summary
• Research In Motion Limited (NASDAQ:RIMM) reported first quarter earnings per share of $1.33. While this is marginally higher than the Zacks Consensus EPS Estimate of $1.32 per share, revenue numbers missed expectations of $5.4 billion by roughly half a billion dollars,...
20Jun2011 | vitalstocks | 0 comments | Continued(ABT) Abbott Labs’ Bardoxolone in Phase III Trials
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with chronic kidney disease and type II diabetes. Study Design The multinational,...
19Jun2011 | vitalstocks | 0 comments | Continued